Thank you. Hello. My name is Martin. I am the CEO of Xbrane Biopharma. I will try to present the company to you. We are engaged in the business of development of biosimilars. A biosimilar is equivalent to generic, but on biological drugs. It is called biosimilar because these are macromolecules, and we cannot demonstrate that they are exactly the same, but they are similar enough.
We have a portfolio of three products here. First, biosimilar to eye drug Lucentis. It is branded Ximluci in Europe, commercialized since three years back by STADA, bringing in about SEK 50 million in profit sharing for sales across Europe and MENA. We recently actually got FDA approval for that same product. Lucamzi is the brand name in the U.S., and we are now gearing up towards a launch mid-next year, together with our partner Valorum.
Next product is a biosimilar candidate to Opdivo, a drug most of you probably are familiar with, PD-1 inhibitor, sales for $10 billion or so a very sizable one. BLA submission to FDA planned mid-next year, and launch upon patent expiration in the U.S., which is December 2028. Then we do biosimilar candidate to Darzalex. It is more early-stage development, but it is targeted for European patent expiration in 2031.
A few words then. Now we are getting into the U.S. with our Lucentis biosimilar. Very sizable market, EUR 9 billion if we think about it as a class of drugs, VEGF inhibitors for ophthalmic purposes. Only if we just take a fraction of this market, it will be very meaningful to us.
I think there are structures in the U.S. which benefits new entrants with the way which how reimbursement is structured under Medicare Part B, and I think we have a good partner in Valorum in place to commercialize this. Now all preparations are underway, applying for the QCO, producing commercial material, and so on and so forth, gearing up towards a launch in the U.S. mid-next year. Very exciting times, I think, for us with regards to this upcoming U.S. launch.
As I said, the product has been on the market in Europe for three years now, commercialized by STADA, on the market in 24 countries. This is a quite simple structure of this arrangement. We are sharing the profit contribution 50/50 with our partner STADA, and they are responsible for commercialization.
This engagement has brought in profit sharing to us of about close to SEK 150 million, so about SEK 50 million a year in profit sharing. That is the level we are at now. We do have an inventory on the balance sheet of about SEK 150 million, which we are converting now to cash during the remainder of this year and during the course of next year.
Then Xdivane. This is probably the biggest opportunity and actually value driver in the company right now, I would say. It targets such a big market. If you include Opdivo and Keytruda, the two main PD-1 inhibitors, it is $40 billion of sales, and we are very well positioned in this race. This is the way it is always with biosimilars. It is a race towards getting to market day one post-patent expiration.
I think we are number one in that race, if you will, just behind Amgen. I do believe we are going to be there day one post-patent expiration. I think we have a good partner here as well, Intas, with their sales subsidiary Accord. They are selling 30% of all oncology injectables across Europe, and they are establishing themselves in the U.S. now as well.
I think we have a very good partner in place, and again, running according to timeline. The clinical trial, the pivotal clinical trial was just fully recruited under Intas' responsibility, 340 patients with melanoma. We have readouts, I think, Q2 next year, and then submission to FDA will be followed shortly thereafter.
I think one very important aspect here is those of you who have followed us and our journey towards an FDA approval with Lucamzi maybe wonder if we are going to get it right the first time when it comes to Xdivane. I do believe we will, and it is important to look one notch below here. We were held back when it comes to Lucamzi due to GMP inspections at our contract manufacturer's production sites, and we have learned a lot from that experience and that journey.
When it comes to Xdivane, we are working with one of the top 10 global contract manufacturers, two European sites on drug substance and drug product respectively, that has been successfully catering FDA inspections since 2010 and supplying commercial goods to the U.S. since.
I think we have reduced significantly the risk when it comes to potential complete response letters due to GMP deficiencies at manufacturing sites for this program. Again, this is key because it centers so much around being there day one in the U.S. post-patent expiration when it comes to biosimilar development. This can be very sizable to us.
We had an external valuation firm looking at this, and they valued the profit sharing that could fall to Xbrane from our partner, that it could peak above EUR 100 million. That would be staggering, of course, for us if that were to materialize. I do believe there is a very significant opportunity for us here and for the company when it comes to the valuation of it. Lastly, few words on Xdarzane early development, but still interesting.
It is a very sizable originator product, $14 billion. We are working with Chinese CMO on this one, JOINN Biologics, which I think will bring now a very cost-competitive production process and also cost-efficient development for this program. We are trying to strike a commercialization deal during the coming 12 months, like what we did with STADA and Intas for the two first programs. That is also something to look out for from a news flow perspective.
Last slide here on the financials. I think we are getting towards now profitability and cash flow positive. We have had quite some journey, and I think we have improved massively in restructurings and deals we have done last couple of years. But now I think it looks very good with the stable profit share we are getting from Ximluci Europe.
The U.S. launch, which from mid next year and onwards will bring in profit sharing to us. Then coming in beginning of 2029, Xdivane launch and profit sharing from that partnership. That's it. Thank you very much for listening and opening up for questions.
Thank you, Martin. Any questions? You mentioned that it's been quite a journey towards profitability. Could you talk a little bit about maybe what is it that you've changed? What are you doing differently that makes you feel that you're now definitely on the right path?
Mainly with regard to the development of Xdivane, selection of contract manufacturers, that was really the big thing. But then also we've reduced our cost base massively. We sold off two-thirds of the company from an employee perspective to Alvotech last year, for example. In doing that, also sold our wet lab activities, as we're now relying fully on collaboration partners for our development. We've changed quite a lot actually, and we come from a position of having close to SEK 500 million in debt to now a very limited debt position. We've restructured quite a lot.
You've done a serious restructure.
Yes.
Yeah. Got a question here. What is your experience on working with the Chinese CRO?
CMO in this case, maybe in the future also CRO, but good. China has really exploded when it comes to pharmaceuticals, generally speaking, biologics manufacturing. I think there are very competent CMOs on the biological side in China and India as well, for that sake. Many are FDA approved, so you can kind of work with them and not having to take that risk, and also very cost efficient. So good so far, yeah.
Let's say final question then. What are the biggest challenges that you see ahead?
I mean, challenges, I think now we are, I should not say this, but on a straight track, I've said it before. Yeah, exactly. I should not say that. But now it feels really like we need to get these balls in again, but it's more things that are within our control, it feels like. We got the FDA approval. That was not fully in our control because we relied on the contract manufacturers and so on.
Now it's up to us and launch, and of course, now we're relying on the commercialization partner to see what it actually generates. But then the big thing is to get the BLA in for Xdivane, but that is under our control, it feels like. I think it's more getting the team together now and actually execute in a timely manner on all these elements, which we believe are going to be value generating for the company. Yeah.
Thank you so much, Martin.
Thank you.